Lehmann K, Plas E, Gautschi K, Hauri D
Urologic Clinic, University Hospital Zürich, Switzerland.
Urol Int. 1994;52(3):159-61. doi: 10.1159/000282597.
The usefulness of routine clinical application of the urokinase plasminogen activator in prostate cancer was evaluated. The urokinase values of prostate cancer confined to the organ, with extraprostatic spread and with metastatic disease did not differ and showed no significant difference in comparison with benign prostatic hyperplasia. Urokinase is not a useful parameter in clinical routine.
评估了尿激酶纤溶酶原激活剂在前列腺癌常规临床应用中的效用。局限于器官内、有前列腺外扩散以及有转移疾病的前列腺癌患者的尿激酶值并无差异，与良性前列腺增生相比也无显著差异。尿激酶在临床常规中并非一个有用的参数。
